Kathmere Capital Management LLC Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

Kathmere Capital Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 7,266 shares of the biopharmaceutical company’s stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Worth Asset Management LLC acquired a new position in Pfizer during the 1st quarter worth $29,000. 25 LLC bought a new position in shares of Pfizer in the first quarter worth about $25,000. Freedom Wealth Alliance LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $35,000. Macroview Investment Management LLC grew its holdings in Pfizer by 70.0% in the 1st quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 396 shares during the last quarter. Finally, Sanctuary Wealth Management L.L.C. bought a new position in Pfizer in the 4th quarter worth approximately $50,000. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $47.00 to $40.00 in a research report on Thursday, June 29th. StockNews.com started coverage on shares of Pfizer in a research report on Thursday, August 17th. They issued a “hold” rating on the stock. Truist Financial reaffirmed a “buy” rating and set a $62.00 price objective on shares of Pfizer in a research report on Wednesday, September 13th. JPMorgan Chase & Co. decreased their target price on Pfizer from $45.00 to $41.00 and set a “neutral” rating on the stock in a research report on Monday, July 17th. Finally, Jefferies Financial Group cut their price target on Pfizer from $40.00 to $38.00 in a report on Wednesday, August 2nd. Twelve analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $46.35.

Pfizer Price Performance

NYSE:PFE opened at $34.07 on Monday. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The firm has a market cap of $192.36 billion, a PE ratio of 9.06, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a 12 month low of $33.54 and a 12 month high of $54.93. The company’s 50-day moving average price is $35.80 and its two-hundred day moving average price is $37.96.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. During the same period in the prior year, the company earned $2.04 EPS. Pfizer’s revenue for the quarter was down 54.1% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 4.81%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio is currently 43.62%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.